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Abstract 
SOX11 is a transcription factor which is proposed to play a role in brain development.  A 
role for SOX11 in human developmental disorders was suggested by a recent report of 
SOX11 mutations in 2 patients with Coffin-Siris syndrome.  Here we further investigate the 
role of SOX11 variants in neurodevelopmental disorders.  We identified 6 individuals with 
chromosome 2p25 deletions involving SOX11.    These individuals had non-syndromic 
intellectual disability with microcephaly, developmental delay and shared dysmorphic 
features.  We next utilised trio exome sequencing to identify 3 novel de novo SOX11 
variants.   Two of these individuals had a phenotype compatible with Coffin-Siris syndrome 
while 1 had non-syndromic intellectual disability.  The pathogenicity of these mutations was 
confirmed using an in vitro gene expression system.   To further investigate the role of loss 
of SOX11 in microcephaly we knocked down SOX11 in xenopus.  Morphants had significant 
reduction in head size compared to controls.  This suggests that SOX11 loss of function can 
be associated with microcephaly.  We thus propose that SOX11 deletion or mutation can 
present with either non-syndromic intellectual disability or a Coffin-Siris phenotype.              
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Introduction 
 The vertebrate SOX protein family consists of 30 genes [Pillai-Kastoori et al, 2015]. The 
SOX genes are classified into 8 subfamilies (SOXA-SOXJ) on the basis of sequence similarity.  
The SOX proteins are transcription factors with a shared motif called the SRY box, a high mobility 
group (HMG) DNA binding domain.  The SOX proteins regulate gene expression, acting as either 
transcriptional activators or repressors, in multiple tissues and so play crucial roles in multiple 
developmental processes [Pillai-Kastoori et al, 2015].   The SOXC subfamily consists of SOX4, 
SOX11 and SOX12. SOX11 is thought to play a crucial role in brain development.  In humans 
neuron production begins on embryonic day 42 and is largely complete by midgestation [Urban & 
Guillemot, 2014].  In the fetus the neuronal progenitors are located in the subventricular zone.  
After production in the subventricular zone neurons migrate outwards into the cortical layers and 
undergo differentiation into mature neurons.  The linked processes of neuronal production from 
progenitor cells and differentiation into functioning neurons must be tightly regulated to ensure 
proper brain development [Urban & Guillemot, 2014].   SOX11 null mice have  reduced cortical 
neurogenesis secondary to reduced proliferation and  abnormal differentiation of neuronal 
progenitor cells [Wang et al, 2013].  This results in SOX11 null mice having reduced brain weights 
and thin cerebral cortices [Wang et al, 2013].  There is also evidence that SOX11 plays a role in 
ocular development.  SOX11 knockdown in zebrafish and xenopus induces microphthalmia with or 
without iris coloboma [Pillai-Kastoori et al, 2014].  The SOX11 gene thus represents a strong 
candidate gene for human neurodevelopmental disease.   
 Haploinsufficiency of other SOX genes is known to cause human disease.  For example, 
mutations in SOX10 are associated with Waardenburg-Hirschprung disease [Pingault et al, 1998], 
and SOX9 mutations with campomelic dysplasia [Kwok et al, 1995]. In contrast, haploinsufficiency 
of SOX5 is reported to cause intellectual disability (PMID: 23498568 and PMID: 23220431).    
Tsurusaki et al (2014) reported 2 children with Coffin-Siris syndrome (CSS, OMIM#125900) and de 
novo mutations in SOX11.  CSS is characterised by developmental delay/intellectual disability, 
feeding difficulties, facial dysmorphology , microcephaly and hypoplastic nails of the fifth digits 
   SOX11 deletions and mutations in human developmental disorders    
4 
[Santen & Clayton-Smith, 2014].  That SOX11 mutations can be associated with CSS provides 
evidence of a role for SOX11 in human brain development.  Both of the mutations reported by 
Tsurusaki et al (2014) affected the HMG DNA binding domain and interfered with the ability of 
SOX11 to induce gene transcription in vitro.  This implicates regulation of gene expression as a 
mechanism by which SOX11 contributes to human brain development.  Multiple genes regulated at 
a transcriptional level by SOX11 have been identified [Sha et al, 2012].  In HEK293 cells 
overexpressing SOX11, 251 genes upregulated by at least 1.5 fold were identified, including 
several genes relevant to neurogenesis (e.g. TUBB3, CD24)[Sha et al, 2012].  SOX11 can also 
repress transcription of genes important for neurodevelopment.  For example, in SOX11 null mice 
LIS1 was upregulated significantly [Wang et al, 2013] and in SOX11 knockdown zebrafish SHH 
was upregulated [Pillai-Kastoori et al, 2014].  Altered levels of SOX11 thus have the potential to 
cause dysregulation of multiple genetic pathways, with clear potential to disrupt developmental 
processes.   
          Here we further investigate a role for SOX11 in human developmental disease.  We identify 
a series of individuals with chromosome 2p25 deletions including SOX11 and 3 individuals with de 
novo SOX11 point mutations.  These individuals had either non-syndromic intellectual disability or 
a mild CSS phenotype.  An in silico analysis demonstrated that expression of SOX11 is highest in 
the brain during early fetal life and rapidly decreases into adulthood, suggesting a role for SOX11 
in human neurodevelopment.  Lastly, knockdown of SOX11 in xenopus larvae was associated with 
microcephaly in the morphants.  Taken together, these data suggest that SOX11 haploinsufficiency 
impairs brain development and is associated with human neurodevelopmental disorders.         
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Materials and methods 
Ascertainment of SOX11 deletion (2p25.2 deletions) and mutation cases 
 Individuals with deletion of chromosome 2p25.2, which included the SOX11 gene, were 
identified through the DECIPHER collaboration and direct contact with investigators involved in 
microarray research programmes. Deletions were confirmed by fluorescent in situ hybridisation 
(FISH). None of the deletions identified were present in the recently published Copy Number 
Variation (CNVs) map of the human genome, which integrates CNV data from healthy individuals 
from multiple datasets [Zarrei et al, 2015]. Two individuals with SOX11 mutations were identified as 
part of the Deciphering Developmental Disorders (DDD) exome sequencing study ((from the data 
freeze of 1133 children).  The methods of DDD are fully described in previous publications [Wright 
et al, 2015]. A third individual with a SOX11 mutation was identified by exome sequencing via the 
Genetics of Structural Brain Abnormalities and Learning Disabilities Study (Wales Research Ethics 
Committee 12/WA/0001) for which the methods have previously been described (PMID: 25855803)  
All mutations were confirmed by Sanger sequencing (supplementary figure 1).   
 
In silico assessment of pathogenicity of novel SOX11 mutations 
 The predicted effect of the SOX11 missense variants was examined using SIFT, Polyphen 
and the “Have Your Protein Explained” tool (http://www.cmbi.ru.nl/hope/home).   Evolutionary 
conservation of mutated amino acids was assessed by aligning orthologues in Ensembl 
(http://www.ensembl.org/index.html).     The presence of SOX11 variants in normal control 
populations was queried using the ExAC browser 
(http://exac.broadinstitute.org/gene/ENSG00000176887).  
 
In vitro assessment of effect of SOX11 mutations on transcriptional activity    
Expression vectors 
The SOX11 open-reading frame clone was purchased from Promega (Tokyo, Japan) and 
SOX11 mutants (c. 150G>C; p. Lys50Asn and c.359C>A; p. Pro120His) generated by site-directed 
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mutagenesis with the KOD-Plus-Mutagenesis Kit (TOYOBO, Osaka, Japan). WT and mutant 
SOX11 cDNAs were PCR amplified and cloned into the p3xFLAG-CMV-14 mammalian expression 
vector (Sigma, St Louis, MO). The GDF5 promoter 5′-flanking sequence (−448/+319) was PCR 
amplified and cloned into the pGL3-basic vector (Promega). All constructs were verified by Sanger 
sequencing. Human SOX11 cDNA can be obtained from GenBank/EMBL/DDBJ nucleotide core 
database under the accession code AB028641.1. 
 
Luciferase reporter assays 
Transfection and luciferase reporter assays were performed as previously described. HeLa cells 
were cultured in Dulbecco's Modified Eagle's. Medium (DMEM) -high glucose supplemented with 
penicillin (50 units / ml), streptomycin (50 μg / ml) and 10% Fetal bovine serum (FBS). Cells were 
plated in 24-well plates, 24 h before transfection, and transfections performed using TransIT-LT1 
(Takara, Ohtsu, Japan) with pGL3 reporter (500 ng / well), effector (250 ng / well) and pRL-SV40 
internal control (6 ng / well) vectors. Twenty-four hours after transfection, cells were harvested and 
luciferase activities measured using the PicaGene Dual SeaPansy Luminescence Kit (TOYO B-
Net, Tokyo, Japan). Production of WT and mutant SOX11 proteins was assessed by immunoblot 
analysis with monoclonal anti-FLAG M2 HRP antibody (1:3,000; Sigma), following the 
manufacturer’s instructions. 
 
In silico assessment of SOX11 expression in developing brain 
 Variation of SOX11 expression levels in the human brain over different developmental 
stages was investigated by analysing RNA-sequencing data from the Brainspan atlas of the 
developing human brain (http://www.brainspan.org/).  Normalised sample-level RNA-seq data was 
downloaded and matched to phenotype data for the brain region and age of each sample.  The 
median and interquartile ranges of Log-2 RPKM (reads per kilobase per million) for SOX11 were 
calculated for each trimester of pregnancy, age 0-10 years, age 10-20 years and age 30-40 years 
for each brain region.  This was done for the cerebellum, hippocampus, striatum and prefrontal 
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cortex.  Alterations in SOX11 RPKM between developmental stages were sought using the 
Kruskall-Wallis test (PASW statistics 18, IBM computing).    
 Variation of SOX11 expression in different anatomical areas of the fetal brain was examined 
using microarray data from the Brainspan atlas from a 15 week female fetus and a 21 week female 
fetus.   SOX11 expression (log2 normalised) was compared between brain areas with high levels 
of neurogenesis (ventricular zone and medial, lateral and caudal ganglionic eminences) and low 
levels (thalamus, cerebellum, brain stem) using the Mann-Whitney U-test (PASW statistics 18, IBM 
computing).       
 
SOX11 knockdown in xenopus larvae 
Xenopus laevis embryos were obtained and cultured according to standard protocols and 
staged as described previously.  All morpholinos (MOs) were obtained by GeneTools, LLC, OR and 
resuspended in DEPC treated water. For loss of function experiments, Sox11 MO (30 ng per 
blastomere) was injected. For control experiments, the standard Control MO suggested by 
GeneTools was used. MOs were injected bilaterally into both dorso-animal blastomeres of 
Xenopus embryos at eight-cell stage to target anterior neural tissue. As a lineage tracer, 0.5 ng gfp 
RNA was co-injected in all experiments to ensure proper injections. For cephalic evaluations 
Xenopus embryos at stage 45 were fixed with formaldehyde and imaged using a Zeiss Axiophot 
microscope. The head area and papillary distance was measured using ImageJ software. Brains of 
representative embryos were dissected using fine tweezers.  Head area and interpupillary distance 
in knockdown and control morphants was compared using the Mann-Whitney u-test (Graphpad 
prism).     
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Results 
Clinical case reports  
Individuals with SOX11 deletions 
 Case 1 is a 12 year old girl, the first child of healthy non-consanguineous parents. There 
was no notable family history.  She was born at 41 weeks of gestation by caesarean section due to 
fetal bradycardia and oligohydramnios.  Birth weight was 3685 g, length 50 cm (50th centile) and 
birth head circumference 35 cm (50th centile).  At the age of 12 years her head circumference was 
50.4 cm (<3rd centile), height 152 cm (25-50th) and weight 44kg (75th centile).  She had global 
developmental delay. She walked without support at 18 months and has poor fine motor skills.  
She started speaking single words at the age of 3 years and 6 months and has had no further 
language development.  She manifests repetitive and stereotyped movements with hyperactivity 
and autism. She had a nonverbal IQ of 54. She was generally well apart from gastro-oesophageal 
reflux.  On examination she has mild facial asymmetry with right microphthalmia and a wide mouth 
with thick lips and large, simplified ears.  Bilateral 5th finger clinodactyly, cutaneous syndactyly of 
toes 2-3, scoliosis and inverted nipples were also noted.   CGH was reported as:                           
arr  2p25(4,269,295-6,823,106)(hg 18)x1 with deletion of  the SOX11 gene only.   The deletion was 
not present in either parent.  
 Case 2 is a 5 years and 11 months old girl, the first child of healthy non-consanguineous 
parents. There was no notable family history. She was born at 36 weeks of gestation by caesarean 
section because of intrauterine growth restriction.  Birth weight was 1,850 g (<10th centile), and  
head circumference 31 cm (<10th centile).  She had developmental delay, first walking 
independently at 22 months old and speaking her first words at 18 months.  At 5 years and 11 
months old, weight was 14.5 kg (<3rd centile), height 102.5 cm (<3rd centile), and OFC 47 cm (<2nd  
centile). She had troublesome gastro-oesophageal reflux.  On examination she was noted to have 
sparse hair, epicanthic folds and a wide mouth with thick lips.  Bilateral clinodactyly of the 4th and 
5th fingers with generalised joint laxity was noted.  A renal ultrasound demonstrated bilateral renal 
hypoplasia. Brain MRI showed agenesis of the posterior third of the corpus callosum.  Formal 
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ophthalmological examination detected a high degree hypermetropia.  CGH was reported as arr 
2p25(5,511,851-16,027,633)(hg 19)x1. The deletion encompassed the SOX11 and MYCN genes.   
The deletion was not present in either parent.   
 Case 3 is a 14 year old girl, the first child of healthy non-consanguineous parents. There 
was no notable family history. She was born at 37 weeks of gestation. Birth weight was 2 840 g (9th 
centile) and head circumference 33 cm  (2nd centile). She had a weak suck and difficulty feeding in 
the neonatal period.  She had developmental delay. She first walked at the age of 20 months.  Her 
fine motor skills were impaired. She had no speech delay.  At 14 years old her height was 158 cm 
(50th) and head circumference was 52 cm (<2nd). She was dysmorphic with a high forehead, 
narrow palpebral fissures, a smooth philtrum, micrognathia and a high arched palate.  A scoliosis, 
inverted nipples, bilateral 5th finger clinodactyly and 2-3 toe syndactyly were noted. CGH was 
reported as: arr 2p25 (5,756,344-6,940,999)(hg 18)x1. The deletion included SOX11, RSAD2 and 
CMPK2. The deletion was not found in the mother. The father was not available for testing.   
 Case 4 is a 25 year old woman, the 3rd child of healthy non-consanguineous parents. There 
was no family history of note.  Pregnancy was complicated by reduced fetal movements.   Birth 
weight was 3130g (25th centile).    Choanal stenosis and persistant ductus arteriosus were present 
in the neonatal period.  She had developmental delay; first walking at 4 years and 8 months and 
speaking her first words at 3 years old. At the age of 25 years old her height was 162 cm (25th 
centile), weight 50kg (10th centile) and head circumference 49cm (<0.4th centile).  She has severe 
intellectual disability and aggressive behaviour. She is physically well but has hypermetropia. On 
examination she was noted to have a flat face with upslanting palpebral fissures and wide mouth 
with thick lips.   Short 2nd fingers with bilateral 5th finger clinodactyly was present along with skin 
syndactyly of toes 2-3 and 4-5 bilaterally.  CGH was reported as: arr 2p25 (5,535,091-
16,398,225)(hg 19)x1 with deletion of SOX11 and MYCN.  The deletion was not found in either 
parent.  
 Case 5 is a 34 year old man, the 3rd child of healthy non-consanguineous parents (previously 
published as patient 16 from the study of De Rocker et al). He was born at term. Birth weight was 
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3750g and length 52cm.  He had intellectual disability, speech delay and epilepsy.  On examination 
at age 34 years height was 150 cm (3rd centile) and head circumference 53 cm (3rd centile, 
corrected for height).  He had facial dysmorphism: microretrognathia, short philtrum and mild 
trigonocephaly.  Scoliosis and cryptorchidism were also noted.  CGH was reported as: arr 
2p25(2,231,163- 8,300,707)(hg 19)x1 with deletion of the SOX11 and MYT1L genes. This was 
paternally inherited, a detailed phenotypic description of the father was not available, but he was 
reported to be epileptic and have intellectual disability and speech delay [De Rocker et al, 2014].    
 Case 6 is a 13 year old girl, who was ascertained via DECIPHER with limited phenotypic 
information available.  She was born at term, small for gestational age.  She presented as an infant 
with feeding difficulties, microcephaly and seizures. She is reported to have delayed speech and 
language development.   On examination she was dysmorphic (low set ears, short nose and short 
philtrum), with clinodactyly of the 5th finger and a single transverse palmar crease.  CGH was 
reported as: arr 2p25(5,209,876-8,078,809)(hg 19)x1. It was not possible to test parental samples.   
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Individuals with SOX11 mutations  
 Case 7 is a 12 years and 6 months old girl, the first child of healthy non-consanguineous 
parents. There was no family history of note. She was born at 41 weeks of gestation. Birth weight 
was 3118g (26th centile).  There was poor feeding in the neonatal period requiring nasogastric 
feeding.  She had global developmental delay; first walking at 2 years and 6 months old.  She has 
never spoken.  At the age of 12 years and 6 months her height was 89.4 cm (-1.7 SD), weight 
12.15 kg (-1.5 SD) and head circumference 46.5 cm (-3.3 SD).  She has profound intellectual 
disability,  severe  autism, absence seizures, bruxism and a tendancy to pick at her skin.  On 
examination facial dysmorphism (sunken eyes, depressed nasomaxillary area and wide mouth with 
thick lips), bilateral 5th finger clinodactyly and hypoplasia of the toe nails of her little toes were 
noted. She had oculomotor dyspraxia.  Her phenotype was felt to be compatible with CSS.  Brain 
MRI was normal. CGH did not demonstrate any pathogenic variants.   Exome sequencing 
identified a de novo, heterozygous missense variant in SOX11 (c.359C>A, p. Pro120His; 
NM_003108.3).  No other plausible pathogenic variants were identified on the exome.   
 Case 8 is an 11 year old boy, the first child of healthy non-consanguineous parents.  There 
was no family history of note.  Pregnancy was complicated by 3rd trimester bleeding.  He was born 
at 40 weeks gestation. Birth weight was 3500g (-0.1SD)  and head circumference was 34.5 cm (-
0.5 SD).  He was readmitted to hospital at 3 weeks of age with poor feeding (immature suck, 
choking and regurgitation of bottle feeds) and failure to thrive. He had global developmental delay; 
first walking at age 2 years and speaking his first words at age 3. At 11 years of age he was 
described as being aggressive with poor attention and no sense of danger. He spoke only in short 
sentences and was in a special needs school.  On examination he was on the 9th centile for height 
and weight and had a head circumference under the 0.4th. He had bilateral conductive deafness, 
cryptorchidism,  hypermetropia and squint. On examination he had facial dysmorphism (malar 
flattening, a short philtrum and tented upper lip) and a left preauricular skin tag.  Bilateral 2-3 
cutaneous toe syndactyly and 5th finger clinodactyly was also noted.  He was felt to have a 
phenotype in keeping with mild CSS.     CGH did not demonstrate any pathogenic variants.  Exome 
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sequencing identified a de novo, missense variant in SOX11 (c.150G>C, p. Lys50Asn).  No other 
plausible pathogenic variants were identified on the exome.   
 Case 9 is a boy with microcephaly, cerebellar vermis atrophy and trigonocephaly. His 
parents were not reported to be consanguineous. His clinical phenotype was one of non-syndromic 
intellectual disability.  Array CGH (180k, Agilent) did not demonstrate any likely pathogenic variants.  
Exome sequencing identified a de novo, nonsense variant in SOX11 (c.87C>A, p. Cys29*).  No 
other plausible pathogenic variants were identified on the exome. 
 
 In silico analysis of SOX11 missense variants 
The c.150G>C (p. Lys50Asn) variant was predicted by SIFT to be deleterious (score of 0) and 
Polyphen to be probably damaging (score of 1).  The  c.359C>A (p. Pro120His) variant was 
predicted by SIFT to be deleterious (score of 0) and by Polyphen to be probably damaging (score 
of 0.996).  Both mutations localise to the HMG (DNA binding) domain. The “Have Your Protein 
Explained” tool identified that in the  c.359C>A (p. Pro120His) variant the mutant residue (histidine) 
is larger and more hydrophilic than the wild type amino acid.  This was predicted to interfere with 
DNA binding and protein-protein interaction. In the c.150G>C (p. Lys50Asn) variant, aspargine is 
noted to be of smaller size and neutral charge compared to the wild type amino acid. This was also 
predicted to interfere with DNA binding.    Both variants are found at evolutionary conserved amino 
acids.  Neither variant was found in the exAC database, nor was the c.87C>A, p. Cys29* mutation.    
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In vitro assessment of effect of SOX11 mutations on transcriptional activity    
SOX11 is known to regulate the GDF5 promotor.  Luciferase reporter assays in HeLa cells indicate 
that both the p. Lys50Asn and p. Pro120His variants display reduced ability to activate the GDF5 
promotor compared to wild type protein.   This suggests that these SOX11 variants interfere with 
the ability of SOX11 to induce gene expression.      
 
Expression of SOX11 in human brain 
For all brain regions examined, SOX11 expression levels (RNA-seq) were highest in the first 
trimester of pregnancy and then fell significantly (Kruskal-Wallis, p<0.01) to reach a nadir in the 4th 
decade of life (figure 5a-5d).  SOX11 expression levels (microarray)  were significantly greater in 
brain areas with high levels of neurogenesis compared to areas of low neurogenesis (Mann-
Whitney U-test p<0.01)(figure 5e) at both 15 weeks and 21 weeks of gestation.     
 
 
 
Knockdown of SOX11 in xenopus  
Knockdown of SOX11 by morpholino injection resulted in a significant reduction in head area and 
interpupillary distance compared to controls (both p<0.01 on Mann-Whitney U-test).  Figure 4 
shows a representative morphant and control. There was no increased death rate amongst the 
morphants compared to controls.  
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Discussion 
 Here we report 6 patients with chromosome 2p25 deletions, which include SOX11, and 3 
individuals with de novo SOX11 point mutations.  The individuals with deletions had several 
phenotypic features in common (table 1).  Microcephaly was reported in all individuals.  All had 
global developmental delay, with particularly marked speech delay.   A shared facial 
dysmorphology of wide mouth and thick lips could be discerned.  Two of the patients reported here 
had trigonocephaly and so it is interesting to note that a 2004 report describes a boy with 
trigonocephaly, cleft palate and multiple minor anomalies with deletion of SOX11 resulting from an 
unbalanced translocation 46,XY,t(2;17)(p25;q24) (PMID: 15540175).  Fifth finger clinodactyly and 
cutaneous syndactyly of toes 2-3 was a frequent examination finding.  None of the deletion cases 
had definite features of CSS such as hypertrichosis, or hypoplasia of the terminal phalanx or nail of 
the 5th digit or 5th toe.  There was, however, considerable variabilty between cases in the number 
and severity of clinical features – likely reflecting the different deletion sizes.  Two of the 3 
individuals with de novo SOX11 variants had features of CSS, similar to those described by 
Tsurusaki et al (2014), while the third had non-specific intellectual disability.  Microcephaly, low 
birth weight and neonatal feeding difficulties associated with hypotonia were frequent findings.  
Developmental delay was reported in all cases apart from Patient 2 in Tsurusaki et al’s report.  
Hypoplasia of the distal phalanx of the 5th finger, broad halluces, 2-3 toe syndactyly and hypoplasia 
of the nail of the 5th toe are also frequent findings.  Ocular abnormalities were present in both 
deletion and mutation cases; case 1 had right microphthalmia, case 2, 4 and 7 had hypermetropia 
and squint while case 7 had oculomotor apraxia  Our report confirms that SOX11 mutations can be 
associated with a CSS phenotype and suggests that SOX11 deletions and mutations can also be 
associated with non-syndromic intellectual disability.        
 The clinical features associated with SOX11 deletion or mutation overlap with a number of 
other dysmorphic syndromes.    Hypoplasia of the 5th fingers with dysmorphism and intellectual 
disability can be observed in conditions such as mosaic trisomy 9 [Burns & Campbell, 2015], 
Deafness-onychodystrophy-osteodystrophy-mental retardation syndrome [Campeau & Hennakem, 
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2014] and phenytoin embryopathy [Sabry & Farag, 1996].  There is also some clinical overlap 
between mild forms of Cornelia de Lange syndrome and individuals with SOX11 mutations [Boyle 
et al, 2014].  However, certain features of CSS, such as the facial dysmorphology, enable 
distinction from these other disorders.        
 Our data suggests that there are 3 broad classes of deletion involving the SOX11 gene.    
Firstly, relatively small deletions centred on SOX11 (case 1, case 3 and case 6).  Secondly, there 
are larger terminal deletions of 2p25.2p24.3 which also involve the MYT1L gene (case 5).  Thirdly, 
there are centromeric deletions which involve SOX11 and MYCN (cases 2 and 4).  The mechanism 
responsible for generating these deletions is unclear – but the lack of common breakpoints implies 
there is no shared genomic cause such as repetitive elements. 
 There are several other genes within the deleted regions which could contribute to the 
observed phenotypes.  In the centromeric deletions (case 2 and 4) it is highly likely that MYCN 
deletion contributes to the phenotype. Deletions and mutations of MYCN are associated with 
Feingold syndrome [Cognet et al, 2011].  The classical features of Feingold syndrome are 
microcephaly, intestinal atresias and brachymesophalangy of the 2nd and 5th fingers.  However, the 
severe intellectual disability reported in case 4 is unusual for individuals with Feingold syndrome 
[Cognet et al, 2011].  In the individual with a telomeric deletion (case 5) loss of MYTL1 is likely to 
contribute to the phenotype. However case 5 has borderline microcephaly, whilst the other 
individuals in the report of De Rocker et al (2014) [De Rocker et al, 2014] who had similar deletions 
involving MYT1L but not SOX11 tended to have macrocephaly.  This suggests that SOX11 
haploinsufficiency may exert a powerful, negative influence on brain growth.      Case 1 has no 
genes other than SOX11 in the deleted region, while the deletion in cases 3 and 6 also contains 
the CMPK2, RSAD2 and RNF144A genes. Deletion of these genes is unlikely to lead to a 
neurodevelopmental disorder. CMPK2 encodes a mitochondrial nucleoside monophosphate kinase 
and heterozygous loss is unlikely to have metabolic consequences [Xu et al, 2008].  RSAD2 
encodes viperin which is an antiviral protein [Upadhyay et al, 2014]. RNF144A is an E3 ubiquitin 
ligase involved in DNA damage repair and apotosis [Ho et al, 2014].  This provides evidence that 
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SOX11 deletion alone can be associated with a neurodevelopmental phenotype.      
 The fact that both heterozygous deletions and mutations of SOX11 are associated with 
microcephaly suggests that loss of function and haploinsufficiency may be the underlying 
mechanism.  The 2 missense variants we describe are within the HMG DNA binding domain (as 
were the 2 previously reported missense variants) while the c.87 C>A variant would be predicted to 
lead to premature termination of translation prior to this domain.    It is thus likely that they will 
interfere with the ability of SOX11 to regulate its target genes.  Our luciferase reporter gene assays 
provide further evidence in support of this as they indicate a reduced ability of mutant SOX11 to 
induce gene expression.  An in vitro study of SOX11 overexpressing cells identified multiple genes 
upregulated by SOX11 which are relevant to neurogenesis and brain development [Sha et al, 
2012].  Examples include FILIP1, which regulates migration of neocortical neurons from the 
ventricular proliferative zone, and GPC2, which is expressed in axonal growth cones [Sha et al, 
2012].  We hypothesise that haploinsufficiency of SOX11 could potentially reduce expression of 
these target genes at critical points in brain development, resulting in a neurodevelopmental 
disorder.             
Data from SOX11 null mice indicate that SOX11 plays an important role in regulating 
neurogenesis [Wang et al, 2013].   The expression pattern of SOX11 in the human brain is also in 
keeping with the gene playing a role in neurogenesis during embryonic development. We show 
that  SOX11 expression peaks in the first 3 months of in utero life and declines thereafter.  Since 
neurogenesis in the fetal brain is largely completed by mid-gestation [Urban & Guillemot, 2014], 
this temporal expression pattern fits with SOX11 being involved in neurogenesis in the fetal brain.  
The spatial expression pattern of SOX11 in fetal brain also suggests that SOX11 is involved in 
neurogenesis, since SOX11 expression was significantly higher in the ventricular zone than in 
areas with relatively low levels of neurogenesis (cerebellum, thalamus, brain stem).  Data from 
animal models also suggests that SOX11 plays an important role in eye development, since 
SOX11 knockdown in zebrafish can cause ocular malformations [Pillai-Kastoori et al, 2014].   In 
addition, variants in SOX11 have also been identified in 2 individuals with iris coloboma and no 
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neurodevelopmental phenotype [Pillai-Kastoori et al, 2014].  This may be explained by the fact that 
the sequence variants in these individuals were not located in the DNA binding HMG domain of 
SOX11 protein, while variants reported herein associated with a neurodevelopmental disorder were 
predicted to interfere with DNA binding.    
Our experiments in xenopus larvae indicate that loss of SOX11 is associated with 
microcephaly.  There was no increased death rate amongst the morphants ; indicating that 
microcephaly was not a non-specific toxic effect of SOX11 knockdown.  The precise mechanism by 
which loss of SOX11 results in microcephaly in xenopus is unclear.  Our previous work on xenopus 
eye development indicates that SOX11 knockdown does not alter proliferation but is associated 
with increased neuronal apoptosis.  This suggests that SOX11 may function as a neuronal survival 
factor in brain development.            
 In conclusion, we describe a series of individuals with SOX11 deletions or de novo 
mutations.  Initially SOX11 mutations were described as being associated with a CSS phenotype, 
and the individuals described here with SOX11 mutations confirm this.  The 2 SOX11 missense 
variants reported here are the only plausibly pathogenic SOX11 variants identified from over 1 000 
exomes performed in the DDD study.  This provides evidence that SOX11 variants are a rare 
cause of neurodevelopmental disorders.   We also report that individuals with SOX11 deletion do 
not have typical clinical features of CSS.  This leads us to suggest that SOX11 deletion or mutation 
can be associated with a phenotype of non-specific intellectual disability or CSS.  Similar findings 
have been reported for the other CSS genes ARID1A and ARID1B [Sim et al, 2015].   Deletion 
mapping, in our small cohort, suggests that SOX11 deletion, although likely pathogenic in itself, 
can also act as part of a contiguous gene deletion along with loss of MYT1L or MYCN.  The 
mechanism is likely to be SOX11 haploinsufficiency with dysregulation of the SOX11 target genes 
and consequent disruption of brain development.  In conclusion, the current study provides 
evidence that SOX11 is a further member of the SOX protein family associated with human 
neurodevelopmental disease.                   
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Figure 1. Schematic diagram of deletions.  
The deletions are displayed as a custom track in UCSC genome browser with refseq genes using 
hg 19.  The black bars represent the deletion in each patient and the 2 dashed vertical lines 
represent the smallest region of overlap.  The smallest region of overlap contains only the SOX11 
gene.    
Figure 2. Clinical photographs of study participants. 
2a. Case 2. Facial photograph in top panel, photograph of hands in lower panel (note 5th finger 
clinodactyly). 2b. Case 4. Facial photograph in top panel, photograph of hands in lower panel (note 
5th finger clinodactyly).  2c. Case 3. Facial photograph in top panel, photograph of hands in lower 
panel (note 5th finger clinodactyly).   2d. Case 1. Facial photograph in top panel.   
2e.  Boy with c.150G>C (p. Lys50Asn) SOX11 mutation (case 7).  Facial photograph in top panel, 
hand in middle panel (note 5th finger clinodactyly) and foot in lowermost panel (note broad hallux 
and 2-3 toe syndactyly).     2f.   Boy with c.87C>A (p. Cys29*) SOX11 mutation (case 9). Facial 
photograph in top panel, hand in middle panel (note 5th finger clinodactyly) and foot in lowermost 
panel (note broad hallux, 2-3 toe syndactyly and hypoplasia of nail of 5th toe).   2g.  Girl with 
c.359C>A (p. Pro120His) SOX11 mutation (case 8).  Facial photograph in top panel, hand in 
middle panel (note 5th finger clinodactyly) and foot in lowermost panel (note broad hallux  and 
hypoplasia of nail of 5th toe).       
Figure 3. SOX11 variants identified in current study. 
3a. Schematic diagram of SOX11 protein demonstrating location of 3 reported sequence variants.  
3b. 3D models demonstrating alteration of SOX11 protein structure associated with the 2 missense 
variants.  Green areas represent the wild type residue while the red area indicates the structure 
adopted by the mutant amino acid.  Both the missense variants were in the DNA binding domain of 
SOX11 and predicted to alter its structure, thus interfering with DNA binding. 
3c. Bar chart demonstrating that the 2 SOX11 missense variants had reduce ability to activate the 
GDF5 promotor in an in vitro reporter system.  The adjacent Western blot confirms that the mutant 
proteins were stably expressed during the experiment.     
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Figure 4. Sox11 knockdown leads to microcephaly in Xenopus laevis.  
4a. Bilateral injection of  Sox11 MO results in significant smaller heads measured by the head area 
(white dotted circles) and the pupillary distance (red lines) compared to bilateral Control MO 
injections. In addition, Sox11 morphants show an eye phenotype as previously described (red 
arrowhead; Cizelsky et al., 2013).  
4b. Statistical evaluation of the measured head area.  
4c. Statistical evaluation of the measured pupillary distance. N, number of individual embryos 
analyzed.  
****, P ≤ 0.0001. P-values were calculated by a non-parametric Mann-Whitney rank sum test.  
 
Figure 5. Expression of SOX11 in developing human brain. 
5a-5d show changes in SOX11 expression levels as measured by rna-sequencing in the 
cerebellum, hippocampus, prefrontal cortex and striatum respectively. Columns labelled first, 
second and third refer to trimesters of pregnancy. Column 10 represents the first decade of life, 20 
the second decade of life and 40 the third and fourth decades. There was a significant decline in 
SOX11 expression levels with increasing age as assessed by the Kruskall-Wallis test (p<0.01).  
5e.  Microarray data demonstrating that SOX11 is expression is higher in brain regions with high 
levels of neurogenesis (periventricular) compared to areas with low levels of neurogenesis 
(cerebellum, thalamus, brain stem), * = p<0.01.  The first 2 columns represent 15 weeks of 
gestation while the second 2 columns represent 21 weeks of gestationg.   
 
